1Van de Werf F,Ardissino D,Betriu A,et al. ESC Guidelines for Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation[J].European Heart Journal,2005,24:28-66.
2Antman EM,Anbe DT,Armstrong PW,et al. ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarc- tion[J].Circulation,2004,110:282-292.
4Fujisaki H,lto H,Hirata Y,et al.Natriuretic Peptides Inhibit Angiotensin I -induced Pro- liferation of Rat Cardiac Fibroblasts by Block- ing Endothelin-1 Gene Expression[J].J Clin Invest, 1995,96:1059-1065.
5Pub lica tion Committee fo r the VM AC Inv estiga to rs.Intra vcno us nesiritide v s n itrog lycer in fo r ty eatm en t o fdeeom peru ated congestive heart failure:a random izedcontro lied trial[J].JAMA,2002,287( 12): 1531 - 1540.
6Peace ckW F,Em erm an C L,Y oung J.N es- iritide in con ge stiv e heart fa ilurc asso c ia ted with acute co ronary syn drom es:A pilot study o f sa fe ty and e fficacy[J].Journa lo f Ca rdiac Fa ilure,201M, 10(2): 120-125.
7Peacock W F,Em erm an C L.Silv er M A.N esiritide added to standard care faro rably re- duees sy sto lie blood pressure corn pared w ith standard care alone in patientsw ithaeute deeom pensa ted heart failure Am J Em e rgM ed[J].Am J Em erg M ed,2005,23(12): 327-331.
8B urg erA J,Ho r ton D P, Le Jem te IT,et al.Ef- feet o f nesir itide(Btype na triure tic pep tide) and do butam ine onventr icu lar arrhy thin ias in the trea tm ent o f patientsw ith aeutely de- corn pensated eo ng estive heart fa ilure:the PRECEDENT study[J].Am Hear t J,2002,144 (6):1102-1108.
二级参考文献15
1[1]Mahon N G, O'Roke, Codd M B, et al. Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart, 1999, 81:478-482.
2[2]Cohn J N, Roberto F, Norman S, et al. Cardiac remodeling-concepte and clinical implications:A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol, 2000, 35:569-582.
3[3]Givertz M M, Collucci W S. New targets for heart-failure therapy: Endothelin ,inflammatory cytokines, oxidative stress. Lancet, 1998, 352(Suppl I):34-38.
4[4]Yousef Z R, Redwood S R, Marber M S. Postinfarction left ventricular remodeling:Where are the theories and trials leading us? Heart, 2000, 83:76-80.
5[5]Vantrimpont P, Rouleau J L, Ciampi A, et al. Two-year course and significance of neurohumoral activation in the survival and ventricular enlargement (SAVE) study. Eur Heart J, 1998, 19:1552-1563.
6[6]Scheuer J. Catecholamines in cardiac hypertrophy. Am J Cardiol, 1999, 83:70-74H.
7[7]Collucci W S. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80: 15L-25L.
8[8]Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med, 1997, 336:1131-1141.
9[9]Aleksandar D, Aleksandar N, Jelera, et al. Acute and long term effect of thrombolysis after anterior wall acute myocardial infarction with serial assessment of infarct expansion and late ventricular remodeling. Am J Cardiol, 1996,77:446-452.
10[10]Marber M S, Taylor D J,Kloner R A. The open artery hypothesis: To open, or not to open, that is the question. Eur Heart J, 1996, 17:505-509.
